Despite these limitations, we believe that our findings provide important new insights for understanding the role of PHB2 in tumorigenesis in NSCLC and suggest that PHB2 could serve as a potential molecular target for the future development of anti-NSCLC therapy. Here, PHB2 is linked to non-small cell lung carcinoma.